- Home
- HSPO vs DBVT Comparison
HSPO vs DBVT Comparison
Compare HSPO & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- DBVT
- Stock Information
- Founded
- HSPO 2014
- DBVT 2002
- Country
- HSPO United States
- DBVT France
- Employees
- HSPO N/A
- DBVT N/A
- Industry
- HSPO Blank Checks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSPO Finance
- DBVT Health Care
- Exchange
- HSPO Nasdaq
- DBVT Nasdaq
- Market Cap
- HSPO 92.0M
- DBVT 102.0M
- IPO Year
- HSPO 2022
- DBVT N/A
- Fundamental
- Price
- HSPO $11.65
- DBVT $4.40
- Analyst Decision
- HSPO
- DBVT Strong Buy
- Analyst Count
- HSPO 0
- DBVT 2
- Target Price
- HSPO N/A
- DBVT $22.50
- AVG Volume (30 Days)
- HSPO 3.5K
- DBVT 28.3K
- Earning Date
- HSPO 01-01-0001
- DBVT 03-06-2025
- Dividend Yield
- HSPO N/A
- DBVT N/A
- EPS Growth
- HSPO 2.63
- DBVT N/A
- EPS
- HSPO 0.28
- DBVT N/A
- Revenue
- HSPO N/A
- DBVT $12,515,000.00
- Revenue This Year
- HSPO N/A
- DBVT N/A
- Revenue Next Year
- HSPO N/A
- DBVT $2,860.00
- P/E Ratio
- HSPO $41.35
- DBVT N/A
- Revenue Growth
- HSPO N/A
- DBVT 125.54
- 52 Week Low
- HSPO $10.80
- DBVT $0.44
- 52 Week High
- HSPO $12.41
- DBVT $5.42
- Technical
- Relative Strength Index (RSI)
- HSPO 48.83
- DBVT 54.39
- Support Level
- HSPO $11.70
- DBVT $4.18
- Resistance Level
- HSPO $11.78
- DBVT $4.47
- Average True Range (ATR)
- HSPO 0.07
- DBVT 0.28
- MACD
- HSPO -0.02
- DBVT -0.04
- Stochastic Oscillator
- HSPO 0.00
- DBVT 71.34
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.